Merck News | finanzen.ch

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Orderbuch			Analysen
Historisch

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Orderbuch

Analysen

Historisch

18.08.23	Merck Announces First Positive Phase 3 Results For WELIREG From LITESPARK-005 (RTTNews)
07.08.23	Anixa Biosciences Announces Opening of Enrollment for Keytruda® Arm in Ongoing Breast Cancer Vaccine Clinical Trial (PR Newswire)
01.08.23	Merck & Co Inc. Q2 Earnings Summary (RTTNews)
28.07.23	Merck: Phase 3 KEYNOTE-756 Trial Meets Primary Endpoint In Early-Stage ER+/HER2- Breast Cancer (RTTNews)
27.07.23	Merck Says 21-valent Pneumococcal Conjugate Vaccine,V116, Meets Key Endpoints In Phase 3 Trials (RTTNews)
25.07.23	Data Vault Holdings, Inc. and p-Chip Corporation to Connect Platforms through Enabling IP Licensing Agreement (PR Newswire)
21.07.23	Merck's Gefapixant Drug For Chronic Cough A Step Away From Approval In Europe (RTTNews)
19.07.23	Merck: Phase 3 KEYTRUDA Trial Meets Primary Endpoint Of PFS In Advanced Cervical Cancer (RTTNews)
27.04.23	Merck Q1 Results Top Estimates; Boosts FY23 Outlook (RTTNews)
16.04.23	Prometheus Biosciences To Be Acquired By Merck (RTTNews)
13.04.23	Merck's KEYTRUDA One Step Closer To Gastric Cancer Treatment Expansion (RTTNews)
12.04.23	Merck: FDA Places Partial Clinical Hold On Initiation Of New Patients On Evobrutinib (RTTNews)
07.04.23	Merck, Eisai Announce Disappointing Results From Phase 3 LEAP-003 And LEAP-017 Trials (RTTNews)
10.03.23	Merck: Phase 2/3 CCTG IND.227/KEYNOTE-483 Trial With KEYTRUDA Meets Primary Endpoint (RTTNews)
01.03.23	Merck: Phase 3 KEYNOTE-671 Trial With KEYTRUDA Meets One Of Its Dual Primary Endpoints (RTTNews)
24.02.23	Merck: CHMP Recommends Against Approval Of Lagevrio For Treatment Of Certain Adults With COVID-19 (RTTNews)
03.02.23	Personalis, Moderna Continue Partnership On Personalized Cancer Vaccine Program (RTTNews)
03.02.23	Merck's KEYTRUDA Plus Chemotherapy Meets Primary Goal As First-Line Therapy In Endometrial Carcinoma (RTTNews)
02.02.23	Merck Q4 Profit Down, Adj. EPS Tops View; Sees Weak FY23 Adj. EPS, Below Market (RTTNews)
27.01.23	Merck's KEYTRUDA Gets FDA Approval To Treat Stage IB, II, IIIA Non-small Cell Lung Cancer Patients (RTTNews)
26.01.23	Merck Animal Health: FDA Approves Expanded Indication For BRAVECTO Chews For Dogs (RTTNews)
20.01.23	Seagen : FDA Grants Accelerated Approval To Tukysa Combination For Colorectal Cancer Treatment (RTTNews)
18.01.23	Merck Selects Perceiv AI for Inaugural Digital Sciences Studio Cohort (PR Newswire)
11.01.23	Merck To Complete Acquisition Of Imago (RTTNews)
30.12.22	China Approves Merck's Covid-19 Drug For Emergency Use (RTTNews)
27.12.22	Biotech Stocks Facing FDA Decision In January 2023 (RTTNews)
22.12.22	Merck, Kelun-Biotech Collaborate To Develop Seven Preclinical ADC For Treatment Of Cancer (RTTNews)
20.12.22	Astellas: PADCEV, KEYTRUDA Granted Priority Review In Treatment Of Metastatic Urothelial Cancer (RTTNews)
20.12.22	Astellas, Seagen and Merck Announce FDA Acceptance of Supplemental Biologics License Applications for PADCEV® (enfortumab vedotin-ejfv) with KEYTRUDA® (pembrolizumab) for the First-Line Treatment ... (PR Newswire)
15.12.22	AstraZeneca: FDA To Extend PDUFA Date Regarding SNDA For Lynparza With Abiraterone (RTTNews)
13.12.22	Moderna, Merck's Phase 2b Trial Of MRNA-4157/V940 Combination In Melanoma Meets Primary Endpoint (RTTNews)
12.12.22	Merck Commences Tender Offer To Acquire Imago BioSciences (RTTNews)
22.11.22	Merck: Phase 3 KEYNOTE-859 Trial Meets Primary Endpoint Of Overall Survival (RTTNews)
21.11.22	Merck To Acquire Imago BioSciences (RTTNews)
14.11.22	AstraZeneca: CHMP Recommends Approval Of Lynparza In Combination With Abiraterone, Prednisone (RTTNews)
08.11.22	Form 4 310158 (RSS)
01.11.22	Veeva and Merck Form Long-Term Strategic Partnership (PR Newswire)
01.11.22	Form 4 310158 (RSS)
27.10.22	Merck Boosts Outlook As Q3 Results Top Estimates (RTTNews)
24.10.22	Merck: European Commission Approves Expanded Indication For VAXNEUVANCE (RTTNews)
18.10.22	Merck Animal Health Launches Sure Petcare Animo® GPS (PR Newswire)
12.10.22	Merck Says Health Canada Granted Approval For KEYTRUDA To Treat Renal Cell Carcinoma (RTTNews)
30.09.22	Biotech Stocks Facing FDA Decision In October 2022 (RTTNews)
27.09.22	AstraZeneca : Japan Approves Koselugo For Rare Genetic Disease In Paediatric Patients (RTTNews)
22.09.22	Merck Animal Health To Buy Vence; Financial Terms Not Disclosed (RTTNews)
22.09.22	U.S. District Court Rules In Favor Of Merck In Patent Infringement Suit Against Viatris (RTTNews)
22.09.22	AstraZeneca Announces Approval Of Lynparza In China (RTTNews)
20.09.22	Merck To Begin Phase 3 Program With Lower Dose Of Islatravir With Doravirine (RTTNews)
13.09.22	Merck: KEYTRUDA Approved In Canada For Adjuvant Treatment Of Patients With Stage IIB Or IIC Melanoma (RTTNews)
12.09.22	Seagen, Astellas, Merck: EV-103 Results Support Investigation Of Enfortumab Vedotin, Pembrolizumab (RTTNews)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

19.11.24		Schwacher Handel: Dow Jones beendet den Dienstagshandel mit Verlusten
19.11.24		Gute Stimmung in New York: NASDAQ 100 letztendlich im Plus
19.11.24		Schwacher Handel: Dow Jones legt am Dienstagnachmittag den Rückwärtsgang ein
19.11.24		Gewinne in New York: NASDAQ 100 legt zu
19.11.24		Dow Jones-Handel aktuell: So entwickelt sich der Dow Jones aktuell
19.11.24		Schwache Performance in Europa: Euro STOXX 50 zeigt sich zum Handelsende schwächer
19.11.24		Angespannte Stimmung in Europa: STOXX 50 verliert schlussendlich

19.11.24

Schwacher Handel: Dow Jones beendet den Dienstagshandel mit Verlusten

19.11.24

Gute Stimmung in New York: NASDAQ 100 letztendlich im Plus

19.11.24

Schwacher Handel: Dow Jones legt am Dienstagnachmittag den Rückwärtsgang ein

19.11.24

Gewinne in New York: NASDAQ 100 legt zu

19.11.24

Dow Jones-Handel aktuell: So entwickelt sich der Dow Jones aktuell

19.11.24

Schwache Performance in Europa: Euro STOXX 50 zeigt sich zum Handelsende schwächer

19.11.24

Angespannte Stimmung in Europa: STOXX 50 verliert schlussendlich

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Givaudan	3’870.00	1.49 %	K V
Lonza Grp	513.60	1.14 %	K V
Swiss Re	125.25	0.20 %	K V
Holcim	88.46	0.11 %	K V
Kuehne+Nagel Int	210.40	0.00 %	K V
Logitech Intl	68.92	-1.20 %	K V
Part Grp Hldg	1’209.00	-1.47 %	K V
CieFinRichemont	118.90	-1.94 %	K V
Nestle	76.66	-1.94 %	K V
Sonova Hldg	300.40	-5.21 %	K V

Nachrichten zu Merck Co.

Aktien Top/Flop

Merck Peer Group Nachrichten

Meistgelesene Nachrichten